Zetia Cost in Maryland 2026: What You'll Actually Pay

What Does Zetia Actually Cost in Maryland in 2026?

Most Maryland patients who pay cash for generic ezetimibe spend around $15 per month, not the $380 brand-name list price. The gap between list price and real-world cost is wide because multiple generic manufacturers now compete in the U.S. market, driving retail prices down sharply since the original Zetia patent expired.

The $380 figure is Merck's Wholesale Acquisition Cost (WAC) for brand-name Zetia. Insurance-negotiated rates, pharmacy benefit manager (PBM) rebates, and generic substitution all reduce what individuals pay at the counter. The FDA's Orange Book confirms bioequivalent generic ezetimibe 10 mg tablets from manufacturers including Amneal, Teva, and Aurobindo are interchangeable with brand Zetia [1].

For the small number of Maryland patients who insist on brand-name Zetia and lack adequate coverage, Merck's savings program may reduce out-of-pocket cost to as little as $15 per month for eligible commercially insured patients. Eligibility requirements exclude Medicare and Medicaid beneficiaries, and the savings card does not apply in Maryland's federally facilitated marketplace plans where it is prohibited by terms of participation.

Cash-pay patients should compare prices across Maryland pharmacies before filling. Prices at CVS, Walgreens, Rite Aid, and independent pharmacies in Baltimore, Bethesda, and Silver Spring can differ by $40 or more for the same 30-day generic supply even within a single zip code. Coupon aggregators such as GoodRx pull real-time pricing from pharmacy processor data and frequently return quotes of $10, $18 for generic ezetimibe 10 mg in Maryland markets [2].

A simple three-step decision framework for Maryland patients:

1. Ask the pharmacist to run generic ezetimibe through your insurance before filling.
2. If the copay exceeds $25, run a GoodRx or RxSaver coupon to compare cash pricing.
3. If both options exceed budget, discuss compounded ezetimibe or a Maryland Medicaid PA with your prescriber.

Why Ezetimibe Is Prescribed: The Clinical Evidence

Ezetimibe works by selectively blocking the NPC1L1 transporter in the small intestine, reducing dietary and biliary cholesterol absorption by roughly 54% [3]. That mechanism is distinct from statins, which inhibit hepatic cholesterol synthesis, making the two drug classes additive.

The landmark IMPROVE-IT trial (N=18,144) compared simvastatin 40 mg alone against simvastatin 40 mg plus ezetimibe 10 mg in patients who had experienced an acute coronary syndrome. After a median 6-year follow-up, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the simvastatin-only arm. The composite cardiovascular endpoint (CV death, nonfatal MI, unstable angina hospitalization, coronary revascularization, or nonfatal stroke) occurred in 32.7% of the combination group versus 34.7% of the simvastatin-only group, an absolute risk reduction of 2.0 percentage points (HR 0.936 to 95% CI 0.89, 0.99, P<0.016) [4]. That trial, published in the New England Journal of Medicine in 2015, established ezetimibe as the first non-statin LDL-lowering agent to demonstrate a reduction in hard cardiovascular outcomes in a randomized controlled trial.

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "In patients with clinical ASCVD in whom LDL-C remains above goal on maximally tolerated statin therapy, ezetimibe is reasonable as the next agent to add" [5]. That guidance drives most Maryland prescriptions for ezetimibe outside primary prevention.

Ezetimibe is also approved as monotherapy for patients who cannot tolerate any statin dose, and as adjunct therapy for heterozygous familial hypercholesterolemia (HeFH) in adults and pediatric patients aged 10 years and older [6]. The FDA label for ezetimibe (NDA 021445) specifies that the drug does not require dose adjustment for mild hepatic impairment, but should be avoided in moderate or severe hepatic impairment [7].

Several systematic reviews have confirmed the LDL-lowering magnitude. A Cochrane analysis of 26 randomized trials found ezetimibe 10 mg reduced LDL-C by a mean of 18.6% as monotherapy and by an additional 21 to 25% when added to a background statin [8]. Those effect sizes are consistent across sex, baseline LDL, and diabetic versus non-diabetic subgroups.

Tolerability is generally excellent. The IMPROVE-IT safety analysis found no statistically significant difference in muscle-related adverse events, liver enzyme elevations, or cancer incidence between ezetimibe and placebo over six years [4]. The FDA label notes that rhabdomyolysis risk, while low for ezetimibe alone, may be increased when it is co-administered with fibrates; that combination warrants monitoring [7].

Maryland Medicaid Coverage for Ezetimibe

Maryland Medicaid (HealthChoice) covers ezetimibe 10 mg tablets for hyperlipidemia, but requires a prior authorization (PA) for most beneficiaries. The PA criteria align with ACC/AHA risk stratification: coverage is generally approved for patients with established ASCVD or familial hypercholesterolemia who have documented statin therapy and an LDL-C above the guideline target.

Maryland Medicaid uses a Preferred Drug List (PDL) maintained by the Maryland Department of Health. Generic ezetimibe appears on the PDL as a non-preferred agent in most managed care organization (MCO) formularies, which triggers the PA step rather than an outright denial [9]. Prescribers in Maryland submit PAs electronically through the Maryland Medicaid Provider Portal or via fax. Typical turnaround for a non-urgent ezetimibe PA is 3, 5 business days.

Patients enrolled in Maryland Medicaid MCOs (Priority Partners, CareFirst BlueCross BlueShield HealthChoice, UnitedHealthcare Community Plan, and others) should confirm coverage with their specific plan, as formulary tier placement can differ between MCOs even within the same state program. Once approved, Maryland Medicaid beneficiaries typically pay $0 to $3 per fill for generic ezetimibe.

The Maryland Children's Health Program (CHIP) covers ezetimibe for pediatric patients meeting the same PA criteria, which is relevant for children diagnosed with HeFH. The American Academy of Pediatrics and the National Lipid Association both recommend statin therapy as first-line in HeFH children aged 8 and older, with ezetimibe added when LDL-C targets are not met [10].

Commercial Insurance Coverage in Maryland

Most commercial insurance plans operating in Maryland place generic ezetimibe on Tier 2 or Tier 3 of their formularies. Tier 2 copays in Maryland typically run $20, $55 per 30-day fill; Tier 3 copays range from $45 to $90 without a coupon. Brand-name Zetia, where covered at all, usually sits on Tier 3 or Tier 4, which can mean $100, $200 per fill under many plans.

Blue Cross Blue Shield of Maryland, CareFirst, Aetna, Cigna, and UnitedHealthcare all include generic ezetimibe on their 2026 formularies, though tier placement varies by plan type (HMO, PPO, HDHP). Patients with high-deductible health plans who have not yet met their deductible pay the full negotiated rate, which is almost always lower than the retail cash price but can still exceed $60, $80 per month early in the plan year.

Medicare Part D beneficiaries in Maryland should use the Medicare Plan Finder tool at medicare.gov to compare formulary placement across PDPs and MA-PD plans in their county. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D, effective January 2025, limits maximum exposure for most Medicare patients who need ezetimibe long-term [11].

Employer-sponsored plans that use CVS Caremark, Express Scripts, or OptumRx as their PBM typically place generic ezetimibe at Tier 2. Employees should confirm the exact copay by logging into their benefits portal or calling the member services number on the back of their insurance card.

Compounded Ezetimibe in Maryland: Is It Legal?

Compounded ezetimibe is legally available in Maryland through pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed prescriber. Maryland has no state-level prohibition on compounding ezetimibe, and multiple 503A pharmacies licensed by the Maryland Board of Pharmacy currently offer it [12].

The distinction between 503A and 503B matters for Maryland patients. Section 503A pharmacies compound for individual prescriptions and are regulated primarily by the Maryland Board of Pharmacy with FDA oversight. Section 503B outsourcing facilities produce larger batches for healthcare facilities and are FDA-registered. Most Maryland patients accessing compounded ezetimibe do so through 503A pharmacies, usually via telehealth prescriptions [13].

Compounded ezetimibe is not FDA-approved, which means the specific formulation has not gone through the same efficacy and manufacturing quality review as brand or generic ezetimibe. Reputable 503A pharmacies in Maryland should hold PCAB (Pharmacy Compounding Accreditation Board) accreditation, which signals adherence to USP <795> standards for non-sterile compounds.

Cost is the main reason patients seek compounded ezetimibe. Some Maryland telehealth platforms that specialize in cardiometabolic care offer compounded ezetimibe as part of a bundled subscription at little to no additional drug cost, bringing the effective monthly price to $0, $25 depending on the platform and included services. That pricing undercuts even generic cash-pay options at retail pharmacies.

Prescribers must write compounded ezetimibe prescriptions for a specific patient; bulk dispensing without a patient-specific prescription violates 503A requirements [12]. Maryland pharmacists are required to counsel patients that compounded ezetimibe is not the same product as FDA-approved Zetia or generic ezetimibe, and that quality controls may differ.

Telehealth Prescribing of Zetia in Maryland

Telehealth prescribing of ezetimibe is fully legal in Maryland for 2026. Maryland law allows licensed physicians, nurse practitioners, and physician assistants to prescribe Schedule VI (non-controlled) medications including ezetimibe after a synchronous audio-video visit that establishes a valid patient-provider relationship [14]. An initial in-person exam is not required for ezetimibe prescriptions under current Maryland law.

The Maryland Board of Physicians and the Maryland Board of Nursing have published guidance consistent with the 2020 flexibilities introduced during the COVID-19 public health emergency, many of which became permanent under Maryland HB 1148 (2023). Ezetimibe, being non-controlled, faces no additional DEA or state prescribing restrictions beyond standard licensing requirements.

Telehealth providers licensed to prescribe in Maryland include large national platforms (Hims, Ro, LifeMD, HealthRX) and Maryland-specific cardiology telehealth services. Patients must provide a valid Maryland address, and the prescriber must hold an active Maryland medical license. Prescriptions can be sent electronically to any Maryland retail or compounding pharmacy.

A telehealth visit for lipid management in Maryland typically costs $50, $150 out-of-pocket if not covered by insurance, though many commercial plans now reimburse telehealth visits at parity with in-person visits under Maryland's telehealth parity law, which has been in effect since 2012 and was expanded in 2021 [14].

Getting the Lowest Price on Ezetimibe in Maryland

The cheapest option for most Maryland patients is generic ezetimibe with a GoodRx, RxSaver, or NeedyMeds coupon at a high-volume pharmacy. Costco Pharmacy and Walmart Pharmacy consistently quote generic ezetimibe 10 mg at $10, $18 per 30-day supply in Maryland markets, often beating independent and chain pharmacy coupon prices.

Maryland's Pharmacy Assistance Program (PAP) and the Maryland Department of Health's drug assistance resources can help uninsured or underinsured residents who do not qualify for Medicaid. The Maryland Access Point (MAP) program connects residents to state and pharmaceutical manufacturer patient assistance programs (PAPs). Merck's PAP, administered through the Merck Patient Assistance Program, provides Zetia at no cost to patients who meet income eligibility criteria (generally at or below 400% of the federal poverty level and without adequate coverage) [15].

NeedyMeds.org lists several ezetimibe-specific manufacturer and nonprofit assistance programs available to Maryland residents. Applications typically require proof of income, a current prescription, and confirmation of insurance status. Processing takes 2 to 6 weeks, so patients should not wait until they run out of medication to apply.

Ordering a 90-day supply instead of 30 days reduces per-unit cost at most Maryland pharmacies by 10 to 20%. Mail-order pharmacy, available through most PBMs and insurance plans, generally provides 90-day supplies at the 60-day copay rate, generating meaningful annual savings for a daily medication.

For Maryland patients who have already maximized statin therapy and need adjunct LDL reduction, combining a 90-day generic ezetimibe supply at $15/month with mail-order delivery represents the most cost-effective non-compounded option available in 2026.

Ezetimibe Versus PCSK9 Inhibitors in Maryland: A Cost Context

When ezetimibe at maximally tolerated statin doses still leaves LDL-C above the ACC/AHA target of <70 mg/dL for very-high-risk ASCVD patients, PCSK9 inhibitors (evolocumab [Repatha] or alirocumab [Praluent]) are the next step. Both are FDA-approved and listed on Maryland Medicaid's PDL with prior authorization [16]. However, their list prices remain $500, $700 per month, orders of magnitude above ezetimibe.

A cost-effectiveness analysis published in JAMA Cardiology found that at prices above $4,536 per year, PCSK9 inhibitors exceed the conventional $100,000/quality-adjusted life-year threshold for cost-effectiveness in secondary prevention [17]. Ezetimibe at $180/year ($15/month) sits far below that threshold, explaining why ACC/AHA guidelines recommend it as the second agent before escalating to PCSK9 inhibitors.

The 2023 ACC Expert Consensus Decision Pathway states: "Ezetimibe should be added before initiating PCSK9 inhibitor therapy in most patients unless LDL-C is severely elevated or clinical urgency warrants earlier escalation" [5]. Maryland Medicaid and most commercial plans use that stepwise approach as a PA prerequisite for PCSK9 inhibitors, meaning proof of an adequate ezetimibe trial is typically required before PCSK9 inhibitor coverage is granted.

Inclisiran (Leqvio), a small-interfering RNA PCSK9 inhibitor dosed twice yearly, received FDA approval in December 2021 and is now available in Maryland through some cardiologists and lipid clinics [18]. Its list price exceeds $3,000 per injection, though net pricing after rebates is lower. Maryland Medicaid coverage requires PA. For the vast majority of Maryland patients, ezetimibe at $15/month remains the appropriate and guideline-concordant first add-on to statin therapy.